Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 57.50 57.00 58.00 57.50 57.50 57.50 946,085 08:00:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 105.6 -22.6 -5.3 - 385

Benchmark Share Discussion Threads

Showing 951 to 973 of 975 messages
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
DateSubjectAuthorDiscuss
31/12/2020
12:00
Nice end to the yr!
edwardt
14/12/2020
13:48
Benchmark (BMK) FY20 analyst presentation Trond Williksen, CEO & Spetima Maguire, CFO present FY20 results to analysts. Video: Https://www.piworld.co.uk/2020/12/14/benchmark-bmk-fy20-results-analyst-presentation/ Podcast: Https://www.piworld.co.uk/podcasts/
tomps2
04/12/2020
12:39
Benchmark Holdings plc transformed operations during FY20 against the challenging macro conditions brought about by Covid-19, completing a fundamental restructuring via nine disposals in a 12-month period. The latter raising up to £44m, with the closure of non-core or loss-making activities allowing a refocus of the business on aquaculture and a rebasing of the cost structure. Consequently, BMK has reinforced its financial position, boosted liquidity by £50m, and appears very well positioned to execute its growth strategy to achieve commercial returns. This leads us to upgrade our FY 21/22 AEBITDA forecasts and to expect a net profit in FY23. The Group is uniquely positioned to build selectively on its leading market positions in aquaculture, notably in developing innovative and sustainable products, diversifying its product range, coupled with a strong focus on profitability and from a position of improved balance sheet strength. We also raise our retained value per share from 63p to 72p on our updated forecasts. While the shares have performed well on the back of successful disposals, those gains look fully justified. https://www.equitydevelopment.co.uk/research/progress-on-the-road-to-profitability
edmonda
03/12/2020
20:46
He mentioned peak margins of 60% for bmk08 on up to 75m sales. If that comes off the share price is off to the races!
edwardt
02/12/2020
14:07
guess others who listened in think so too!
edwardt
02/12/2020
12:06
peter george is a no nonsense chap - he gets my vote!
edwardt
30/10/2020
15:21
anyone know why we are flying?
edwardt
15/10/2020
13:56
something fishy going on here?
edwardt
21/9/2020
20:17
The launch of CleanTreat® + BMK08 to combat sea lice is on track. CleanTreat has not been proven as a commercially viable system and data to demonstrate the system’s efficacy has not been subject to scientific scrutiny. For me, it is a nice story at best, that is all. BMK08 is I believe based on imidacloprid - is that really the best they could come up with, seriously? Hardly cutting edge is it? They may well yet go onto exceed predictions but not on the examples you cite, for sure not long term.
st augustus
09/9/2020
09:23
Management at Benchmark Holdings are doing as they promised: the disposals program is nearly complete, raising £44m which boosts financial strength. The launch of CleanTreat® + BMK08 to combat sea lice is on track. Equity Development keeps its fair value at 63p/share, read new research note here: https://tinyurl.com/y54mhj3a
edmonda
26/8/2020
15:02
someone wants them.
edwardt
24/8/2020
10:28
guess the city is buying into the focus narrative. hard not to agree that is the way forward. clean treat and salmon genetics should be enough. A mini genus in the making?
edwardt
23/7/2020
10:53
I hate middle men. 4million for selling something worth 16m -completely wrong on my mind. Pen pushers need to be erased. Rant over. Stock up so guess irrelevant
edwardt
23/7/2020
10:39
Massive update.Fire work soon.https://www.investegate.co.uk/benchmark-hlgs-plc--bmk-/rns/sale-of-vaccine-manufacturing-assets/202007231105018934T/
36jay
21/7/2020
11:50
For cash you need products that are attractive, and for products in this sector, you need scientists, preferably good ones.
st augustus
07/7/2020
15:26
divestments make sense to me - time to run this for cash not as an r&d play thing for scientists.
edwardt
16/6/2020
05:05
Salmon - covid link
albanyvillas
08/6/2020
10:20
Couple of decent Director purchases advised. Comforting sign.
murdo mcsponge
05/6/2020
20:54
There have been some big blocks moving recently. I wonder. Is something afoot?
murdo mcsponge
03/6/2020
19:42
What caused the spike today I wonder!!
edwardt
03/6/2020
15:46
#BMK Genetics division was resilient, ongoing restructuring and cost containment a priority, DCF valuation of BMK is £421m or 63 pence per share https://research.equitydevelopment.co.uk/research/streamlined-for-growth-and-efficiency
edmonda
02/4/2020
15:16
Latest note on BMK and how they're coping with COVID-19 is here: https://equitydevelopment.co.uk/edreader/?d=%3D%3DQOwcjM
edmonda
09/3/2020
11:32
after the successful raise of £43m and Q1 result, new research is out with increased sales and EBITDA forecasts. Analyst's fair value rises to £479m, or 72p / share, with product launches and disposals to look forward to. Click here for free access to note: https://tinyurl.com/tp22gso
edmonda
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
ADVFN Advertorial
Your Recent History
LSE
BMK
Benchmark
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210228 01:47:31